
Psychedelics-focused mental health company Novamind Inc. (CSE:NM) (OTCQB:NVMDF) (FSE: HN2) reported its financial results for the three and six months ended December 31, 2021.
“We’re pleased to report record high revenue this quarter driven by continued revenue growth from existing and new clinics," Novamind CEO, Yaron Conforti, stated. "Novamind is focused on providing clinical research services to leading drug developers, meeting patient demand by delivering innovative, evidence-based mental healthcare and bringing to market new treatment programs such as Psychedelic Palliative Care by Novamind and Frontline KAP.”